Business
HLS Therapeutics Announces that Amarin's Vascepa ® (icosapent ethyl) Demonstrates 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attack and Stroke in REDUCE-IT(TM), which Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite Endpoint
HLS Therapeutics Announces that Amarin's Vascepa ® (icosapent ethyl) Demonstrates 26%...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nHLS Therapeutics Announces that Amarin's Vascepa ® (icosapent ethyl) Demonstrates 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attack and Stroke in REDUCE-IT™, which Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite Endpoint\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Nov. 12, 2018\n\n\n\nCardiovascular Death Reduced by 20% Fatal or Nonfatal Heart Attacks Reduced by 31% Fatal or Nonfatal Stroke Reduced by 28% Urgent or Emergent Coronary Revascularization Reduced by 35% Hospitalization for Unstable Angina Reduced by 32% Number Needed to Treat for Primary Composite Endpoint: 21 HLS has the Exclusive Rights to Vascepa for the Canadian Market TORONTO, Nov. 12, 2018 /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX-V:HLS) announces that Amarin Corporation plc (NASDAQ:AMRN) released primary results from the Vascepa® (icosapent ethyl) cardiovascular (\"CV\") outcomes trial, REDUCE-IT™, at the 2018 Scientific Sessions of the American Heart Association (\"AHA\") in Chicago, Illinois on Saturday November 10, 2018.  REDUCE-IT primary results confirmed 25% relative risk reduction (\"RRR\") for the topline primary endpoint result with multiple robust demonstrations of efficacy, including 20% reduction in cardiovascular death. HLS has in-licensed the exclusive rights to Vascepa for the Canadian market. Vascepa has not been submitted to Health Canada for regulatory approval and is not approved for use in Canada.\nCardiovascular benefits appeared not to be influenced significantly by triglyceride (\"TG\") levels at baseline (135 mg/dL to 499 mg/dL baseline range) or as achieved at on...